Cargando…

Tigecycline Dosing Strategies in Critically Ill Liver-Impaired Patients

This study investigated tigecycline exposure in critically ill patients from a population pharmacokinetic perspective to support rational dosing in intensive care unit (ICU) patients with acute and chronic liver impairment. A clinical dataset of 39 patients served as the basis for the development of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Amann, Lisa F., Alraish, Rawan, Broeker, Astrid, Kaffarnik, Magnus, Wicha, Sebastian G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9028393/ https://www.ncbi.nlm.nih.gov/pubmed/35453230 http://dx.doi.org/10.3390/antibiotics11040479

Ejemplares similares

Pharmacokinetics of tigecycline in critically ill patients with liver failure defined by maximal liver function capacity test (LiMAx)
por: Alraish, Rawan, et al.
Publicado: (2020)

Stability studies with tigecycline in bacterial growth medium and impact of stabilizing agents
por: Amann, Lisa F., et al.
Publicado: (2020)

Tigecycline in critically ill patients on continuous renal replacement therapy: a population pharmacokinetic study
por: Broeker, A., et al.
Publicado: (2018)

Pharmacokinetics of high-dose tigecycline in critically ill patients with severe infections
por: De Pascale, Gennaro, et al.
Publicado: (2020)

Assessing parameter uncertainty in small-n pharmacometric analyses: value of the log-likelihood profiling-based sampling importance resampling (LLP-SIR) technique
por: Broeker, Astrid, et al.
Publicado: (2020)

Population pharmacokinetics of tigecycline in critically ill patients
por: Luo, Xiangru, et al.
Publicado: (2023)

Impact of Inaccurate Documentation of Sampling and Infusion Time in Model-Informed Precision Dosing
por: Alihodzic, Dzenefa, et al.
Publicado: (2020)

High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria
por: De Pascale, Gennaro, et al.
Publicado: (2014)

The pharmacokinetics of tigecycline in critically ill adult patients undergoing CVVHD
por: Rypulak, E, et al.
Publicado: (2015)

Progression of Fibrinogen Decrease during High Dose Tigecycline Therapy in Critically Ill Patients: A Retrospective Analysis
por: Treml, Benedikt, et al.
Publicado: (2021)

The blind spot in high-dose tigecycline pharmacokinetics in critically ill patients: membrane adsorption during continuous extracorporeal treatment
por: Honore, Patrick M, et al.
Publicado: (2015)

Best tigecycline dosing for treatment of infections caused by multidrug-resistant pathogens in critically ill patients with different body weights
por: Ibrahim, Mohamed M, et al.
Publicado: (2018)

Clinical characteristics and risk factors of tigecycline-associated hypofibrinogenaemia in critically ill patients
por: Hu, Juan, et al.
Publicado: (2020)

Preliminary experience of tigecycline treatment in critically ill children with ventilator-associated pneumonia
por: Lin, Shupeng, et al.
Publicado: (2018)

Genomic and Phenotypic Evolution of Tigecycline-Resistant Acinetobacter baumannii in Critically Ill Patients
por: Zhang, Jiangang, et al.
Publicado: (2022)

Evaluation of the Robustness of Therapeutic Drug Monitoring Coupled with Bayesian Forecasting of Busulfan with Regard to Inaccurate Documentation
por: Dadkhah, Adrin, et al.
Publicado: (2021)

Operational characteristics of full random effects modelling (‘frem’) compared to stepwise covariate modelling (‘scm’)
por: Amann, Lisa F., et al.
Publicado: (2023)

High-dose tigecycline use in severe infections
por: De Pascale, G, et al.
Publicado: (2013)

Impact of Tigecycline’s MIC in the Outcome of Critically Ill Patients with Carbapenemase-Producing Klebsiella pneumoniae Bacteraemia Treated with Tigecycline Monotherapy—Validation of 2019′s EUCAST Proposed Breakpoint Changes
por: Papadimitriou-Olivgeris, Matthaios, et al.
Publicado: (2020)

Once Daily High Dose Tigecycline Is Optimal: Tigecycline PK/PD Parameters Predict Clinical Effectiveness
por: Baron, Jeffrey, et al.
Publicado: (2018)

Tigecycline use in critically ill patients: a multicentre prospective observational study in the intensive care setting
por: Montravers, Philippe, et al.
Publicado: (2014)

Tigecycline Therapy for Infections Caused by Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae in Critically Ill Patients
por: Yu, Wen-Liang, et al.
Publicado: (2020)

Tigecycline pharmacokinetics in critically ill patients on renal replacement therapy: possible warnings and potential perspectives for the research agenda
por: Cutuli, Salvatore Lucio, et al.
Publicado: (2020)

Establishment and Validation of a Liquid Chromatography-Tandem Mass Spectrometry Method for the Determination of Tigecycline in Critically Ill Patients
por: Yao, Fen, et al.
Publicado: (2020)

Acute-on-chronic liver failure alters linezolid pharmacokinetics in critically ill patients with continuous hemodialysis: an observational study
por: Tikiso, Tjokosela, et al.
Publicado: (2023)

An Integrated Dialysis Pharmacometric (IDP) Model to Evaluate the Pharmacokinetics in Patients Undergoing Renal Replacement Therapy
por: Broeker, Astrid, et al.
Publicado: (2020)

Correlation between plasma endothelin-1 levels and severity of septic liver failure quantified by maximal liver function capacity (LiMAx test). A prospective study
por: Kaffarnik, Magnus F., et al.
Publicado: (2017)

Effect of pharmacokinetic/pharmacodynamic ratio on tigecycline clinical response and toxicity in critically ill patients with multidrug-resistant Gram-negative infections
por: Ruiz, Jesus, et al.
Publicado: (2020)

Early diagnosis of liver failure in septic patients using the maximal liver function capacity test (LiMAx test): comparison with conventional methods
por: Kaffarnik, M, et al.
Publicado: (2013)

Tigecycline as a Second-Line Agent for Legionnaires’ Disease in Severely Ill Patients
por: Slawek, Deepika, et al.
Publicado: (2017)

Voriconazole Pharmacokinetics Are Not Altered in Critically Ill Patients with Acute-on-Chronic Liver Failure and Continuous Renal Replacement Therapy: An Observational Study
por: Grensemann, Jörn, et al.
Publicado: (2021)

Acinetobacter Prosthetic Joint Infection Treated with Debridement and High-Dose Tigecycline
por: Vila, Andrea, et al.
Publicado: (2016)

Population Pharmacokinetics of High-Dose Tigecycline in Patients with Sepsis or Septic Shock
por: Borsuk-De Moor, Agnieszka, et al.
Publicado: (2018)

Hypofibrinogenemia induced by high-dose tigecycline—case report and review of literature
por: Fan, Qiaomei, et al.
Publicado: (2020)

Cutaneous Hyperpigmentation Secondary to High-Dose Tigecycline: A Case Report
por: Alsemari, Muhannad A., et al.
Publicado: (2020)

The liver in critical illness
por: Hawker, Felicity H.
Publicado: (2008)

Comparable Efficacy of Tigecycline versus Colistin Therapy for Multidrug-Resistant and Extensively Drug-Resistant Acinetobacter baumannii Pneumonia in Critically Ill Patients
por: Kim, Won-Young, et al.
Publicado: (2016)

Efficacies of Colistin–Carbapenem versus Colistin–Tigecycline in Critically Ill Patients with CR-GNB-Associated Pneumonia: A Multicenter Observational Study
por: Wang, Sheng-Huei, et al.
Publicado: (2021)

Ceftazidime–Avibactam-Based Versus Tigecycline-Based Regimen for the Treatment of Carbapenem-Resistant Klebsiella pneumoniae-Induced Pneumonia in Critically Ill Patients
por: Shi, Ying, et al.
Publicado: (2021)

Rational use of tigecycline and tigecycline blood concentration monitoring in patients with severe infection
por: Yu, Meiling, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_0h6bad88lf2ii2bgjjtc7kv3p8